JP2010537623A - 前立腺癌を治療する方法及び組成物 - Google Patents

前立腺癌を治療する方法及び組成物 Download PDF

Info

Publication number
JP2010537623A
JP2010537623A JP2010500022A JP2010500022A JP2010537623A JP 2010537623 A JP2010537623 A JP 2010537623A JP 2010500022 A JP2010500022 A JP 2010500022A JP 2010500022 A JP2010500022 A JP 2010500022A JP 2010537623 A JP2010537623 A JP 2010537623A
Authority
JP
Japan
Prior art keywords
androgen
polypeptide
testosterone
prostate
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010500022A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010537623A5 (enExample
Inventor
クリストファー ホーヴェンス
ナイアル コーコラン
アンソニー コステロ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2007901628A external-priority patent/AU2007901628A0/en
Application filed by Individual filed Critical Individual
Publication of JP2010537623A publication Critical patent/JP2010537623A/ja
Publication of JP2010537623A5 publication Critical patent/JP2010537623A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2010500022A 2007-03-27 2008-03-26 前立腺癌を治療する方法及び組成物 Pending JP2010537623A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2007901628A AU2007901628A0 (en) 2007-03-27 Methods and compositions for treating prostate cancer
US94528207P 2007-06-20 2007-06-20
US99063707P 2007-11-28 2007-11-28
PCT/AU2008/000424 WO2008116262A1 (en) 2007-03-27 2008-03-26 Methods and compositions for treating prostate cancer

Publications (2)

Publication Number Publication Date
JP2010537623A true JP2010537623A (ja) 2010-12-09
JP2010537623A5 JP2010537623A5 (enExample) 2011-05-12

Family

ID=39787967

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010500022A Pending JP2010537623A (ja) 2007-03-27 2008-03-26 前立腺癌を治療する方法及び組成物

Country Status (6)

Country Link
US (2) US20100092477A1 (enExample)
EP (1) EP2137213A4 (enExample)
JP (1) JP2010537623A (enExample)
AU (1) AU2008232311A1 (enExample)
CA (1) CA2681917A1 (enExample)
WO (1) WO2008116262A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018515445A (ja) * 2015-05-18 2018-06-14 ネッレ セラピューティクス リミテッドＮｅｒｒｅ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 性ホルモン依存性疾患を治療するためのｎｋ−１／ｎｋ−３受容体デュアルアンタゴニスト

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009033212A1 (en) * 2007-09-11 2009-03-19 Christopher Hovens The use of estrogen and androgen binding proteins in methods and compositions for treating gynaecological cancers
US20110144032A1 (en) * 2008-08-08 2011-06-16 Christopher Hovens Biological applications of steroid binding domains
CA2786535C (en) 2010-01-11 2019-03-26 Curna, Inc. Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg
KR101183615B1 (ko) * 2011-12-28 2012-09-17 재단법인 경기과학기술진흥원 Ｗｎｔ에 결합하는 신규한 재조합 단백질
WO2014152640A1 (en) * 2013-03-15 2014-09-25 Invivis Pharmaceuticals Inc. Assay for predictive biomarkers of anti-androgen efficacy
CN120605334B (zh) * 2025-08-11 2025-11-04 核工业总医院 Fbxo2在治疗前列腺癌中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307030B1 (en) * 1988-04-15 2001-10-23 The University Of North Carolina At Chapel Hill Androgen receptor proteins, recombinant DNA molecules coding for such, and use of such compositions
JPH04356427A (ja) * 1991-02-26 1992-12-10 Keisuke Hirasawa 免疫賦活剤
GB9809951D0 (en) * 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6117639A (en) * 1998-08-31 2000-09-12 Vertex Pharmaceuticals Incorporated Fusion proteins, DNA molecules, vectors, and host cells useful for measuring protease activity
DK1436003T3 (da) * 2001-05-24 2010-03-15 Zymogenetics Inc TACI-immunoglobulin-fusionsproteiner
EP1673395A1 (en) * 2003-10-15 2006-06-28 PDL BioPharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
US20060246511A1 (en) * 2005-04-27 2006-11-02 B&C Biotech Methods of determining levels of steroid fractions utilizing SHBG calculations
GB0614568D0 (en) * 2006-07-21 2006-08-30 Haptogen Ltd Anti-testosterone antibodies

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018515445A (ja) * 2015-05-18 2018-06-14 ネッレ セラピューティクス リミテッドＮｅｒｒｅ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 性ホルモン依存性疾患を治療するためのｎｋ−１／ｎｋ−３受容体デュアルアンタゴニスト

Also Published As

Publication number Publication date
AU2008232311A1 (en) 2008-10-02
US20130064821A1 (en) 2013-03-14
WO2008116262A1 (en) 2008-10-02
US20100092477A1 (en) 2010-04-15
CA2681917A1 (en) 2008-10-02
EP2137213A4 (en) 2010-06-09
EP2137213A1 (en) 2009-12-30

Similar Documents

Publication Publication Date Title
ES2707551T3 (es) Métodos y composiciones para tratar enfermedades tumorales
CN104662044B (zh) 用于治疗ror1癌症并抑制转移的抗体和疫苗
US20130064821A1 (en) Methods and compositions for treating prostate cancer
BR112019020508A2 (pt) anticorpos biespecíficos de ligação a erbb-2 e erbb3 para utilização no tratamento de células que possuem um gene de fusão nrg1
JP2012507299A (ja) Ｌｉｇｈｔ標的分子およびその使用
JP2018521019A (ja) 抗ｏｘ４０抗体を使用して癌を治療する方法
BRPI0519775B1 (pt) Proteína isolada de ligação a antígeno, polinucleotídeo isolado, plasmídio e célula isolada e composição farmacêutica
HK1251474A1 (zh) 使用抗ox40抗体和pd-1轴结合拮抗剂治疗癌症的方法
EP3177640A2 (en) High affinity pd-1 agents and methods of use
BR122022012930B1 (pt) Anticorpo anti-cgrp ou fragmento de anticorpo anti-cgrp, sequências de ácido nucleico, vetor, célula cultivada ou recombinante, composição farmacêutica e uso do referido anticorpo ou fragmento de anticorpo
WO2016023001A1 (en) Multispecific high affinity pd-1 agents and methods of use
JP2014510265A (ja) Ｉｇｆ−１ｒの阻害に関する方法および組成物
JP2024028805A (ja) がん処置のための坑ｉｌ－８抗体及び坑ｐｄ－１抗体を用いる組合せ治療
WO2021190637A1 (en) Combination of anti-her2 antibody and cdk inhibitior for tumor treatment
JP2024513692A (ja) グレムリン１アンタゴニストを使用して疾患を処置する方法
CN117157317A (zh) 用于治疗异常子宫出血的IL-11或IL-11Ra的抑制剂
EP3294301A1 (en) Compounds and compositions useful for treating or preventing cancer metastasis, and methods using same
US20220008570A1 (en) Combination of radioimmunotherapy and immune checkpoint therapy in the treatment of cancer
US20100291086A1 (en) Use of estrogen and androgen binding proteins in methods and compositions for treating gynaecological cancers
CN115397418A (zh) 使用选择性糖皮质激素受体调节剂刺激抗肿瘤反应的方法
JP2022514087A (ja) ＩＬ－１β結合抗体の使用
CN121079314A (zh) 用于组合疗法的方法和组合物
JP2023516885A (ja) 選択的グルココルチコイド受容体モジュレーター（ｓｇｒｍ）及び抗体チェックポイント阻害剤による副腎皮質がん腫の処置
Gopi et al. Advances in Prostate Cancer Treatment: Exploring Molecular Targets and New Strategies in Castration-Resistant Disease
WO2007010628A1 (ja) 癌の予防・治療剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110325

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110325

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A073

Effective date: 20120730